{"id":32712,"date":"2025-07-09T16:00:53","date_gmt":"2025-07-09T10:30:53","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32712"},"modified":"2025-07-09T16:00:54","modified_gmt":"2025-07-09T10:30:54","slug":"empasiprubart-phase-ii-arda-study","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study","title":{"rendered":"EAN 2025: Empasiprubart Shows Proof-of-concept in MMN with Reduced IVIg Dependence and Biomarker Improvements"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li><em>Empasiprubart significantly <\/em><strong><em>delayed IVIg retreatment<\/em><\/strong><em> and <\/em><strong><em>improved grip strength and patient-reported outcomes<\/em><\/strong><em> in both MMN cohorts.<\/em><\/li>\n\n\n\n<li><em>Biomarker shifts, including <\/em><strong><em>reduced serum NfL levels<\/em><\/strong><em>, indicate <\/em><strong><em>axonal preservation and reinforce the neuroprotective potential<\/em><\/strong><em> of <\/em><strong><em>C2 inhibition<\/em><\/strong><em>.<\/em><\/li>\n<\/ul>\n\n\n\n<p>At <strong>European Academy of Neurology (EAN) 2025<\/strong>, data from the <strong>Phase II ARDA study<\/strong> (NCT05225675) provided compelling proof-of-concept evidence for <strong>empasiprubart<\/strong>, a <strong>novel C2 complement inhibitor,<\/strong> in treating multifocal motor neuropathy (MMN). MMN is a chronic, immune-mediated neuropathy characterized by asymmetric limb weakness and axonal degeneration, with complement activation via the classical and lectin pathways playing a central role in its pathogenesis. By targeting complement component C2, empasiprubart interrupts this cascade at an upstream point, offering a potentially disease-modifying approach.<\/p>\n\n\n\n<p>The ARDA study enrolled 27 adults with definite or probable MMN who were IVIg-dependent and on stable IVIg regimens. Participants were randomized 2:1 to receive empasiprubart or placebo within two cohorts. Cohort 2 included older patients with longer disease duration and prior IVIg exposure. The <strong>primary efficacy endpoint<\/strong> was <strong>time to first IVIg retreatment <\/strong>during the Double-blind Treatment Period (DBTP), along with <strong>secondary endpoints<\/strong> including <strong>grip strength, Patient Global Impression of Change (PGIC), and serum neurofilament light chain (NfL chain levels)<\/strong>.<\/p>\n\n\n\n<p>Empasiprubart demonstrated a favorable safety profile, with adverse events mostly mild or moderate in severity. Importantly, it significantly delayed the need for IVIg retreatment. In <strong>Cohort 1<\/strong>, the <strong>hazard ratio (HR<\/strong> for retreatment was <strong>0.09 (95% CI: 0.02, 0.44)<\/strong>, while in <strong>Cohort 2<\/strong> it was <strong>0.17 (95% CI: 0.02, 1.60)<\/strong>, <strong>both favoring empasiprubart over placebo<\/strong>. This suggests a meaningful reduction in relapse risk and supports the potential to reduce IVIg dependence.<\/p>\n\n\n\n<p>Patient-reported outcomes also favored empasiprubart. In <strong>Cohort 1<\/strong>, <strong>56%<\/strong> of patients treated with <strong>empasiprubart<\/strong> reported being \u201c<strong>very much\u201d or \u201cmuch improved\u201d vs. 11% in the placebo group<\/strong>. In <strong>Cohort 2<\/strong>,<strong> 66.6%<\/strong> of <strong>empasiprubart-treated patients<\/strong> reported similar improvement vs. <strong>22.2%<\/strong> <strong>with placebo<\/strong>. Notably, more patients on the placebo reported deterioration in their condition.<\/p>\n\n\n\n<p><strong>An objective functional benefit<\/strong> was also observed. In <strong>Cohort 1<\/strong>, the <strong>median change in grip strength<\/strong> was <strong>+11.28 kPa (Q1\u2013Q3: 0.00\u201328.78) with empasiprubart<\/strong>, compared to only <strong>+0.89 kPa (\u20130.67 to 9.00) with placebo<\/strong>. In <strong>Cohort 2<\/strong>, grip strength improvement reached <strong>+19.89 kPa (3.33\u201338.89) vs. +0.78 kPa (\u20132.22 to 7.89)<\/strong>, further demonstrating treatment-related gains in motor function. Additionally, <strong>serum NfL levels decreased<\/strong> in both cohorts following empasiprubart treatment, suggesting preservation of axonal integrity and reinforcing its neuroprotective mechanism of action.<\/p>\n\n\n\n<p><strong>KOL View<\/strong><\/p>\n\n\n\n<p>Empasiprubart, which remains in development for other conditions like delayed graft function, dermatomyositis, and chronic inflammatory demyelinating polyneuropathy, is designed to be a humanized sweeping antibody that binds specifically to C2 in a pH\u2013 and Ca2+ dependent manner. By blocking complement activity, the belief is that this therapy may reduce tissue inflammation and the adaptive immune response. Notably, the agent is engineered for a long half-life through increased affinity to FcRn at acidic pH. <strong>\u2013 Expert Opinion<\/strong><\/p>\n\n\n\n<p><strong>Conclusion<\/strong><\/p>\n\n\n\n<p>The ARDA study marks a pivotal advance in MMN treatment, positioning empasiprubart as a <strong>safe and potentially disease-modifying therapy<\/strong>. By selectively inhibiting complement C2, it led to meaningful improvements in grip strength, reduced IVIg dependence, and signs of axonal preservation, validating complement activation as a key driver of disease. Empasiprubart may address a critical unmet need in MMN where no approved disease-modifying therapies currently exist. These results support empasiprubart not as an adjunct, but as a targeted, biomarker-driven therapy that could redefine MMN care. With a Phase III trial already underway, further validation in a broader population will be key to confirming its long-term efficacy and establishing a new standard of care.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>At European Academy of Neurology (EAN) 2025, data from the Phase II ARDA study (NCT05225675) provided compelling proof-of-concept evidence for empasiprubart, a novel C2 complement inhibitor, in treating multifocal motor neuropathy (MMN). MMN is a chronic, immune-mediated neuropathy characterized by asymmetric limb weakness and axonal degeneration, with complement activation via the classical and lectin pathways [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":32714,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[22601],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-32712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-ean-annual-congress","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Empasiprubart Phase II ARDA Study | EAN 2025<\/title>\n<meta name=\"description\" content=\"The ARDA study enrolled 27 adults with definite or probable MMN who were IVIg-dependent and on stable IVIg regimens.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Empasiprubart Phase II ARDA Study | EAN 2025\" \/>\n<meta property=\"og:description\" content=\"The ARDA study enrolled 27 adults with definite or probable MMN who were IVIg-dependent and on stable IVIg regimens.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T10:30:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-09T10:30:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09155956\/empasiprubart-phase-ii-arda-study.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Empasiprubart Phase II ARDA Study | EAN 2025","description":"The ARDA study enrolled 27 adults with definite or probable MMN who were IVIg-dependent and on stable IVIg regimens.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study","og_locale":"en_US","og_type":"article","og_title":"Empasiprubart Phase II ARDA Study | EAN 2025","og_description":"The ARDA study enrolled 27 adults with definite or probable MMN who were IVIg-dependent and on stable IVIg regimens.","og_url":"https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-07-09T10:30:53+00:00","article_modified_time":"2025-07-09T10:30:54+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09155956\/empasiprubart-phase-ii-arda-study.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study","url":"https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study","name":"Empasiprubart Phase II ARDA Study | EAN 2025","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09155956\/empasiprubart-phase-ii-arda-study.png","datePublished":"2025-07-09T10:30:53+00:00","dateModified":"2025-07-09T10:30:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The ARDA study enrolled 27 adults with definite or probable MMN who were IVIg-dependent and on stable IVIg regimens.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/empasiprubart-phase-ii-arda-study#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09155956\/empasiprubart-phase-ii-arda-study.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09155956\/empasiprubart-phase-ii-arda-study.png","width":466,"height":284,"caption":"empasiprubart-phase-ii-arda-study"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/07\/09155956\/empasiprubart-phase-ii-arda-study-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">EAN Annual Congress<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">EAN Annual Congress<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 months ago","modified":"Updated 10 months ago"},"absolute_dates":{"created":"Posted on Jul 9, 2025","modified":"Updated on Jul 9, 2025"},"absolute_dates_time":{"created":"Posted on Jul 9, 2025 4:00 pm","modified":"Updated on Jul 9, 2025 4:00 pm"},"featured_img_caption":"empasiprubart-phase-ii-arda-study","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32712"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32712\/revisions"}],"predecessor-version":[{"id":32715,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32712\/revisions\/32715"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32714"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32712"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32712"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}